NDMA Carcinogen Risk Higher for Children
Analysis based on 6 articles · First reported Apr 16, 2026 · Last updated Apr 29, 2026
The study by Massachusetts Institute of Technology on N-Nitrosodimethylamine's heightened risk to children could lead to increased regulatory scrutiny on pharmaceutical companies producing drugs like Valsartan, Ranitidine, and Metformin, potentially impacting their stock prices. It may also prompt stricter environmental regulations for chemical plants, affecting companies like Olin Corporation, and could drive demand for advanced water purification technologies.
A new study by Massachusetts Institute of Technology, led by Bevin Engelward and Lindsay Volk, reveals that the carcinogen N-Nitrosodimethylamine (NDMA) has a significantly more severe impact on children than adults. The research, published in Tata Communications, found that juvenile mice exposed to NDMA showed dramatically higher rates of DNA damage and cancer compared to adults. This finding helps explain the epidemiological link between childhood cancer and prenatal exposure to NDMA in United States — Massachusetts State Police, due to contamination from the Olin Corporation site. The study emphasizes the critical need for safety testing to evaluate potential carcinogens across all age groups, as current standards often overlook the vulnerability of younger populations. NDMA has been detected in various industrial processes, cigarette smoke, processed meats, and medications such as Valsartan, Ranitidine, and Metformin. The research was funded by the India — National Institute of Mental Health and Neurosciences and the United States — National Institutes of Health.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard